The systemic lupus erythematous (SLE) disease autoantigen - Calreticulin can inhibit C1q association with immune complexes

Clinical and Experimental Immunology

Volumn 108, Issue 2, 1997, Pages 181-190

  Kishore, U ^a   Sontheimer, R D ^c   Sastry, K N ^b   Zappi, E G ^c   Hughes, G R V ^d   Khamashta, M A ^d   Reid, K B M ^a   Eggleton, P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

C1q; calreticulin; immune complexes; systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CALCIUM; CALRETICULIN; COMPLEMENT COMPONENT C1Q; GLOBULAR PROTEIN; HYBRID PROTEIN; MAGNESIUM; MALTOSE BINDING PROTEIN; RECOMBINANT PROTEIN; CALCIUM BINDING PROTEIN; COMPLEMENT INHIBITOR; IMMUNOGLOBULIN G; RIBONUCLEOPROTEIN;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL SURFACE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT FIXATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLAMMATION; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN DOMAIN; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; BINDING SITE; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PROTEIN BINDING;

ADULT; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; AUTOANTIGENS; BINDING SITES; CALCIUM-BINDING PROTEINS; CALRETICULIN; COMPLEMENT C1Q; COMPLEMENT INACTIVATOR PROTEINS; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROTEIN BINDING; RIBONUCLEOPROTEINS;

EID: 0030611105     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.3761273.x     Document Type: Article

References (37)

1. Cochrane CG, Koffler D. Immune complex disease in experimental animals and man. Adv Immunol 1973; 16:185-253.
2. Schifferli JA, Bartolotti SR, Peters DK. Inhibition of immune precipitation by complement. Clin Exp Immunol 1980; 42:387-94.
3. Colomb MG, Arlund GJ, Villiers CL. Structure and activation of C1: current concepts. Complement 1984; 1:69-80.
4. Atkinson JP. Complement deficiency: predisposing factor to autoimmune syndromes. Clin Exp Rheumatol 1989; 7(S-3):S95-S101.
5. Sontheimer RD, Lieu T-S, Capra JD. The diverse functional repertoire of calreticulin, a new human autoantigen. The Immunologist 1993; 1:155-60.
6. Martinez-Lavin M, Vaughan JH, Tan EM. Auto-antibodies and the spectrum of Sjogren's syndrome. Ann Intern Med 1979; 91:185-90.
7. Sontheimer RD, Maddison PJ, Reichlin M et al. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Int Med 1982; 97:664-71.
8. Michalak M, Milner RE, Burns K et al. Calreticulin. Biochem J 1992; 285:681-92.
9. Unnasch T, Gallin MY, Soboslay PT et al. Isolation and characterization of expression cDNA clones encoding antigens of Onchocerca volvulus infective larvae. J Clin Invest 1988; 82:262-9.
10. Khalife J, Trottein F, Schacht AM et al. Cloning of the gene encoding a Schistosoma mansoni antigen homologous to human Ro/SS-A autoantigen. Mol Biochem Parasitol 1993; 57:193-202.
11. Zhu J, Newkirk MN. Viral induction of the human autoantigen calreticulin. Clin Invest Med 1994; 17:196-205.
12. White TK, Zhu Q, Tanzer ML. Cell surface calreticulin is a putative mannoside lectin which triggers mouse melanoma cell speading. J Biol Chem 1995; 270:15926-9.
13. Sueyoshi T, McMullen BA, Marnell LL et al. A new procedure for the separation of protein Z, prothombin fragment 1.2 and calreticulin from human plasma. Thromb Res 1991; 63:569-75.
14. Eggleton P, Lieu T-S, Zappi EG et al. Calreticulin is released from activated neutrophils and binds to CIq and mannan binding protein. Clin Immunol Immunopathol 1994; 72:405-9.
15. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
16. Zappi EG, Haseman CA, Lieu T-S et al. Expression of the human 46kDa Ro/SS-A autoantigen (calreticulin) as a recombinant protein (Abstr). Clin Res 1991; 39:496A.
17. McCauliffe DP, Lux FA, Lieu T-S et al. Molecular cloning, expresion and chromosome 19 localization of a human Ro/SS-A autoantigen. J Clin Invest 1990; 85:1379-91.
18. Eggleton P, Wang L, Penhallow J et al. Differences in oxidative response of subpopulations of neutrophils from healthy subjects and patients with rheumatoid arthritis. Ann Rheum Dis 1995; 54:916-23.
19. Reid KBM. Preparation of human C1q, a subcomponent of the first component of the classical pathway of complement. Methods Enzymol 1981; 80:16-25.
20. Lieu T-S, Newkirk M, Capra JD et al. Molecular characterization of human Ro/SS-A antigen: amino acid terminal sequence of the protein moiety of human Ro/SS-A antigen and immunological activity to a corresponding synthetic peptide. J Clin Invest 1988; 82:96-101.
21. di-Guan C, Li P, Riggs P et al. Vectors that facilitate the expression and purification of foreign peptides in Escherichia coli by fusion to maltose binding protein. Gene 1988; 67:21-30.
22. Kishore U, Sontheimer RD, Sastry KN et al. Release of calreticulin from neutrophils may alter C1q-mediated immune functions. Biochem J 1997; 332:543-50.
23. 2+ binding domains. J Biol Chem 1991; 266:21458-65.
24. Ohkuro M, Kobayashi K, Takahashi Ket al. Effect of C1q on the processing of immune complexes by human neutrophils. Immunol 1994; 83:507-11.
25. Routsias JG, Tzioufas AG, Sakarellos-Daitsiotis M et al. Calreticulin synthetic peptide analogues: anti-peptide antibodies in autoimmune rheumatic diseases. Clin Exp Immunol 1993; 91:437-41.
26. Hunter FA, Barger BD, Schrohenloher R et al. Autoantibodies to calreticulin in the sera of systemic lupus erthematosus. Arthritis Rheum 1991; 34:575.
27. Lux FA, McCauliffe DP, Buttner DW et al. Serological cross-reactivity between a human Ro/SS-A autoantigen (calreticulin) and the lambda Ral-1 antigen of Oncherca volvulus. J Clin Invest 1992; 89:1945-51.
28. Zhou Y, Dziak E, Unnasch TR et al. Major retinal cell components recognized by onchocerciasis are associated with the cell surface and nucleoli. Invest Opthal Vis Sci 1994; 35:1089-99.
29. Kuwabara K, Pinsky D, Schmidt A et al. Calreticulin, an antithrombotic agent which binds to vitamin K-dependent coagulation factors, stimulates endothelial nitric oxide production, and limits thrombosis in canine coronary arteries. J Biol Chem 1995; 270:8179-87.
30. Davies K, Peters AM, Beynon HLC et al. Immune complex processing in systemic lupus erythematosus-in vivo imaging and clearance studies. J Clin Invest 1992; 90:2075-83.
31. Davies KA, Schifferli JA, Walport MJ. Complement deficiency and immune complex disease. Spring Sem Immunopathol 1994; 15:397-416.
32. Bobak DA, Frank MM, Tenner AJ. C1q acts synergistically with phorbol dibutyrate to activate CR1-mediated phagocytosis by human mononuclear macrophages. Eur J Immunol 1988; 18:2001-7.
33. Guan EG, Burgess WH, Robinson SL et al. Phagocytic cell molecules that bind to the collagen-like region of C1q: involvement in the C1q-mediated enhancement of phagocytosis. J Biol Chem 1991; 266:20345-55.
34. Eggleton P, Ghebrehiwet B, Coburn JP et al. Characterization of the human neutrophil C1q receptor and functional effects of free ligand on activated neutrophils. Blood 1994; 84:1640-9.
35. Eggleton P, Kishore U, Leigh LEA et al. Identification of C1q-binding proteins associated with the plasma membrane of human neutrophils. Mol Immunol 1996; 33:88.
36. Eggleton P, Ghebrehiwet B, Sastry KN et al. Identification of a gC1q-binding protein (gC1qR) on the surface of human neutrophils: subcellular localization and binding properties in comparison with the cC1q-R. J Clin Invest 1995; 95:1569-78.
37. Ahmed AEE, Veitch J, Whaley K. Mechanism of action of an inhibitor of complement-mediated prevention of immune precipitation. Immunol 1990; 70:139-44.